Biotech Archives - RNA Advisors

RNA|July 25 2019|Client Success, Strategic Advisory, Valuation Advisory

Client Success: Incremental Borrowing Rate Analysis for Publicly Traded, Clinical Stage Biotech

THE PROBLEM: A publicly traded clinical stage biotech company needed to understand the correct implied discount rate for a lease agreement in accordance with ASC 842 rules. THE SOLUTION: ASC 842 has specific rules relating to leases, including guidance on lease classification (operating versus financial) and how to discount a lessee’s lease payments to arrive

RNA|October 20 2016|Client Success, Valuation Advisory

Derivatives Valuation for pre-IPO Biotechnology Company

THE PROBLEM: A development stage biotechnology company (considering an IPO in the near future) entered into a series of financings which required the valuation of components of the financings deemed to be a derivative for financial reporting purposes. THE SOLUTION: RNA worked with the company and their Big 4 auditor to develop a Monte Carlo